IN THE CLAIMS

Please amend the claims as follows:

Claims 1-10 (Cancelled).

Claim 11 (Currently Amended): A compound of the formula:



or a pharmaceutically acceptable salt thereof,

wherein

Y is lower alkylene;

R^1 is phenyl which is substituted with 1 or 2 same or different substituent(s) selected from the group consisting of halogen, lower alkyl, lower alkoxy, mono(or di or tri)halo(lower)alkyl, nitro, amino, lower alkylamino, di(lower)alkylamino, lower alkylthio, lower alkylsulfonyl, cyclo(lower)alkylsulfonyl, aminosulfonyl, lower alkylaminosulfonyl, di(lower)alkylaminosulfonyl, pyrrolidinylsulfonyl, morpholinylsulfonyl, pyrrolylsulfonyl, pyridylsulfonyl, pyrrolyl and pyridyl;

R^2 is phenyl which is substituted with hydroxy and a substituent selected from the group consisting of lower alkyl, mono(or di or tri) halo (lower) alkyl, mono (or di or tri)halo(lower)alkylsulfonyloxy, halogen, lower alkylenedioxy, lower alkoxy, lower alkoxycarbonyl, lower alkoxy(lower)alkoxy(lower)alkoxy, hydroxy, diphenyl(lower)alkylsilyloxy, tri(lower)alkylsilyloxy, hydroxy(lower)alkyl, cyano, amino,

[mono(or di or tri)halo(lower)alkylcarbonyl]amino, lower alkylamino, N-(lower alkyl)-[mono(or di or tri)halo(lower)alkylcarbonyl]amino, pyrrolidinyl and morpholinyl which may be substituted with lower alkoxy(lower)alkyl or lower alkyl;

R^3 is hydrogen; and

R^4 is (2,6-dimethylmorpholino)(lower)alkyl; (3,3-dimethylmorpholino)(lower)alkyl; (cis-3,5-dimethylmorpholino)(lower)alkyl; ((3S,5S)-3,5-dimethylmorpholino)(lower)alkyl; ((3S,5R)-3,5-dimethylmorpholino)(lower)alkyl; (2-methoxymethylmorpholino)(lower)alkyl; (3-methoxymethylmorpholino)(lower)alkyl; (2-methoxymethyl-5-methylmorpholino)(lower)alkyl; (2-methoxymethyl-5,5-dimethylmorpholino)(lower)alkyl; (3,5-dimethoxymethylmorpholino)(lower)alkyl; or (2,3-dimethoxymethylmorpholino)(lower)alkyl.

Claim 12 (Previously Presented): The compound of claim 11, in which

Y is C_1-C_4 alkylene;

R^1 is bis [mono (or di or tri) halo (C_1-C_4) alkyl] phenyl;

R^2 is phenyl which is substituted with hydroxy and a substituent(s) selected from the group consisting of C_1-C_4 alkyl, mono (or di or tri) halo(C_1-C_4) alkyl, halogen, C_1-C_4 alkoxy and hydroxy;

R^3 is hydrogen; and

R^4 is (2,6-dimethylmorpholino) (C_1-C_4) alkyl; (2-methoxymethylmorpholino) (C_1-C_4)alkyl; (3-methoxymethylmorpholino) (C_1-C_4) alkyl; or (2-methoxymethyl-5-methylmorpholino) (C_1-C_4) alkyl.

Claim 13 (Previously Presented): The compound of claim 12, which is selected from the group consisting of

(1) 1-[3,5-Bis(trifluoromethyl)benzoyl]-2-(3-hydroxy-4-methylbenzyl)-4-[2-[(3R)-3-(methoxymethyl)morpholino]-ethyl]piperazine,

(2) 1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[2-(cis-2,6-dimethylmorpholino)ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine,

(3) 1-[3,5-Bis(trifluoromethyl)benzoyl]-2-(3-hydroxy-4-methylbenzyl)-4-[2-[(2S,5S)-2-methoxymethyl-5-methylmorpholino]ethyl]piperazine,

(4) 1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine,

(5) (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine, and

(6) (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-2-(4-chloro-3-hydroxybenzyl)-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]piperazine,

or a pharmaceutically acceptable salt thereof.

Claim 14 (Previously Presented): A process for the preparation of the compound, or a salt thereof, of claim 11, which comprises,

reacting a compound of the formula (II), or a salt thereof:



(II)

with a compound of the formula (III), or a salt thereof:

$$W_1\text{-}R^4 \qquad \text{(III)}$$

wherein W_1 is a leaving group, to give a compound of the formula (I), or a salt thereof:



(I)

wherein R^1, R^2, R^3, R^4 and Y are each as defined in claim 11.

Claim 15 (Previously Presented): A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 11 or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutical acceptable carrier.

Claim 16 (Currently Amended): A method for treating ~~or preventing~~ Tachykinin-mediated diseases of asthma, emesis, ~~mental diseases~~ anxiety disorders, pollakiuria, urinary incontinence or irritable bowel syndrome, which comprises administering an effective amount of a compound, or a pharmaceutically acceptable salt thereof, of claim 11 to a human being or an animal.

Claim 17 (Previously Presented): The compound of claim 13, which is (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine, or a pharmaceutically acceptable salt thereof.

Claim 18 (Previously Presented): The compound of claim 17, which is (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[2-[(2S)-2-(methoxymethyl)morpholino]ethyl]-2-(3-hydroxy-4-methylbenzyl)piperazine dihydrochloride.

DISCUSSION OF THE AMENDMENT

Claim 11 has been amended by reciting the salt as --pharmaceutically acceptable--. Claim 16 has been amended by deleting "preventing" and by replacing "mental diseases" with --anxiety disorders--, as supported in the specification, at page 23.

No new matter has been added by the above amendment. With entry thereof, Claims 11-18 will remain pending in the application.